[go: up one dir, main page]

MX2009007242A - Compuesto de [1,2,3]-benzotriazinona 3-sustituida para mejorar respuestas sinapticas glutamatergicas. - Google Patents

Compuesto de [1,2,3]-benzotriazinona 3-sustituida para mejorar respuestas sinapticas glutamatergicas.

Info

Publication number
MX2009007242A
MX2009007242A MX2009007242A MX2009007242A MX2009007242A MX 2009007242 A MX2009007242 A MX 2009007242A MX 2009007242 A MX2009007242 A MX 2009007242A MX 2009007242 A MX2009007242 A MX 2009007242A MX 2009007242 A MX2009007242 A MX 2009007242A
Authority
MX
Mexico
Prior art keywords
treatment
compound
substituted
synaptic responses
glutamatergic synaptic
Prior art date
Application number
MX2009007242A
Other languages
English (en)
Inventor
Alexis Cordi
Gary Rogers
Rudolf Mueller
Original Assignee
Cortex Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortex Pharma Inc filed Critical Cortex Pharma Inc
Publication of MX2009007242A publication Critical patent/MX2009007242A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Esta invención se refiere a la prevención y tratamiento de insuficiencia cerebral, que incluye el mejoramiento del funcionamiento de receptores en sinapsis en redes cerebrales responsables de los comportamientos de orden superior. Estas redes cerebrales están implicadas en las capacidades cognitivas relacionadas con el deterioro de la memoria, como se observa en una gama de demencias, y en los desequilibrios en la actividad neuronal entre diferentes regiones cerebrales, como se sugiere en trastornos tales como la enfermedad de Alzheimer, esquizofrenia y trastornos afectivos. En un aspecto particular, la presente invención se refiere a un compuesto útil para el tratamiento de tales condiciones, y a métodos de uso de este compuesto para tal tratamiento.
MX2009007242A 2007-01-03 2007-12-28 Compuesto de [1,2,3]-benzotriazinona 3-sustituida para mejorar respuestas sinapticas glutamatergicas. MX2009007242A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87850307P 2007-01-03 2007-01-03
US92143307P 2007-04-02 2007-04-02
PCT/US2007/026416 WO2008085506A1 (en) 2007-01-03 2007-12-28 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses

Publications (1)

Publication Number Publication Date
MX2009007242A true MX2009007242A (es) 2009-09-02

Family

ID=39608956

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009007242A MX2009007242A (es) 2007-01-03 2007-12-28 Compuesto de [1,2,3]-benzotriazinona 3-sustituida para mejorar respuestas sinapticas glutamatergicas.

Country Status (37)

Country Link
US (1) US8173644B2 (es)
EP (1) EP2144506B1 (es)
JP (1) JP5139446B2 (es)
CN (1) CN101616592B (es)
AP (1) AP2502A (es)
AR (1) AR064740A1 (es)
AT (1) ATE527269T1 (es)
AU (1) AU2007342365B2 (es)
BR (1) BRPI0720749A2 (es)
CA (1) CA2674460C (es)
CR (1) CR10906A (es)
CU (1) CU23804B7 (es)
CY (1) CY1112493T1 (es)
DK (1) DK2144506T3 (es)
EA (1) EA017437B1 (es)
EC (1) ECSP099499A (es)
ES (1) ES2374995T3 (es)
GE (1) GEP20125438B (es)
GT (1) GT200900189A (es)
HN (1) HN2009001268A (es)
HR (1) HRP20110970T1 (es)
IL (1) IL199651A (es)
MA (1) MA31160B1 (es)
ME (1) ME00819B (es)
MX (1) MX2009007242A (es)
MY (1) MY154877A (es)
NI (1) NI200900131A (es)
NZ (1) NZ578293A (es)
PL (1) PL2144506T3 (es)
PT (1) PT2144506E (es)
RS (1) RS52108B (es)
SG (1) SG163545A1 (es)
SI (1) SI2144506T1 (es)
SV (1) SV2009003322A (es)
TN (1) TN2009000277A1 (es)
WO (1) WO2008085506A1 (es)
ZA (1) ZA200904826B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2114158B1 (en) * 2007-01-03 2012-08-08 Cortex Pharmaceuticals, Inc. 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
CN101742911A (zh) 2007-05-17 2010-06-16 科泰克斯药品公司 用于增强谷氨酸能突触反应的二取代的酰胺
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
BRPI0823262A2 (pt) 2007-08-10 2013-09-24 Cortex Pharma Inc mÉtodo de tratamento de depressço respiratària e uso de um composto na fabricaÇço de um medicamento para o tratamento de depressço respiratària
US20110257186A1 (en) * 2010-04-15 2011-10-20 Staubli Ursula V Compositions and methods for treating visual disorders
US9242938B2 (en) 2011-11-22 2016-01-26 Beijing Medisan Technology Co., Ltd Glycine reuptake inhibitor and use thereof
FR3019464B1 (fr) * 2014-04-07 2016-05-06 Servier Lab Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
FR3034019B1 (fr) 2015-03-26 2017-03-17 Servier Lab Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un antidepresseur et les compositions pharmaceutiques qui la contiennent
CA2988572A1 (en) * 2015-06-26 2016-12-29 Takeda Pharmaceutical Company Limited 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
CN106226509B (zh) * 2016-08-12 2019-09-06 中国人民解放军第四军医大学 一种在小鼠前扣带回皮层诱发dse现象的方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3723436A (en) 1971-02-25 1973-03-27 Sun Oil Co Process for aromatic lactams
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
FR2597103B1 (fr) 1986-04-15 1988-12-16 Provesan Sa Procede de preparation de derives d'oxazinobenzothiazine 6,6-dioxyde
PT651746E (pt) 1992-07-24 2002-09-30 Univ California Drogas que intensificam as respostas sinapticas mediadas por receptores de ampa
US5962477A (en) * 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
EP0709384B1 (de) * 1994-10-31 1998-12-23 MERCK PATENT GmbH Benzylpiperidinderivate mit hoher Affinität zu Bindungsstellen von Aminosäure-Rezeptoren
US5650409A (en) 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5736543A (en) 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
US6030968A (en) 1996-09-17 2000-02-29 The Regents Of The University Of California Positive AMPA receptor modulation to enhance brain neurotrophic factor expression
US6110935A (en) * 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
US5985871A (en) 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response
HUP0101280A3 (en) 1998-02-18 2003-02-28 Neurosearch As Positive ampa receptor modulator compounds and their use
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
US6303542B1 (en) * 2000-08-18 2001-10-16 Rohm And Haas Company Herbicidal 3-substituted-phenyl-1,2,3-benzotriazin-4-ones
UA79940C2 (en) * 2001-11-26 2007-08-10 Cortex Pharma Inc Carbonylbenzoxazine compounds for enhancing of glutamatergic synaptic responses
JP2003238555A (ja) * 2002-02-20 2003-08-27 Sumitomo Pharmaceut Co Ltd 細胞死抑制剤
AUPS255202A0 (en) * 2002-05-27 2002-06-13 Monash University Agents and methods for the treatment of disorders associated with motor neuron degeneration
JP2006516283A (ja) * 2003-01-13 2006-06-29 コーテックス ファーマシューティカルズ, インコーポレイテッド 睡眠不足とストレスに起因する知覚衰退の処置方法
GB0317482D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
EP2114158B1 (en) 2007-01-03 2012-08-08 Cortex Pharmaceuticals, Inc. 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
CN101742911A (zh) 2007-05-17 2010-06-16 科泰克斯药品公司 用于增强谷氨酸能突触反应的二取代的酰胺
BRPI0823262A2 (pt) 2007-08-10 2013-09-24 Cortex Pharma Inc mÉtodo de tratamento de depressço respiratària e uso de um composto na fabricaÇço de um medicamento para o tratamento de depressço respiratària
CN101801939A (zh) * 2007-09-20 2010-08-11 科泰克斯药品公司 用于增强谷氨酸能突触反应的3-取代1,2,3-三嗪-4-酮类和3-取代1,3-嘧啶酮类

Also Published As

Publication number Publication date
BRPI0720749A2 (pt) 2014-01-14
ME00819B (me) 2012-03-20
JP2010514838A (ja) 2010-05-06
DK2144506T3 (da) 2012-03-05
JP5139446B2 (ja) 2013-02-06
SI2144506T1 (sl) 2012-01-31
HK1140105A1 (en) 2010-10-08
ECSP099499A (es) 2009-10-30
AP2009004931A0 (en) 2009-08-31
PL2144506T3 (pl) 2012-04-30
AR064740A1 (es) 2009-04-22
GT200900189A (es) 2011-08-02
NZ578293A (en) 2012-01-12
CY1112493T1 (el) 2015-12-09
CU23804B7 (es) 2012-03-15
AU2007342365B2 (en) 2012-11-15
AU2007342365A1 (en) 2008-07-17
CN101616592A (zh) 2009-12-30
PT2144506E (pt) 2011-12-21
IL199651A0 (en) 2010-04-15
AP2502A (en) 2012-10-23
SV2009003322A (es) 2010-02-05
NI200900131A (es) 2010-03-11
US20100137295A1 (en) 2010-06-03
US8173644B2 (en) 2012-05-08
MA31160B1 (fr) 2010-02-01
CA2674460C (en) 2014-07-15
HN2009001268A (es) 2011-12-27
GEP20125438B (en) 2012-03-26
ATE527269T1 (de) 2011-10-15
CA2674460A1 (en) 2008-07-17
IL199651A (en) 2015-08-31
TN2009000277A1 (en) 2010-10-18
EP2144506B1 (en) 2011-10-05
SG163545A1 (en) 2010-08-30
EP2144506A1 (en) 2010-01-20
EA200900925A1 (ru) 2009-12-30
EP2144506A4 (en) 2010-05-05
ES2374995T3 (es) 2012-02-23
RS52108B (sr) 2012-08-31
CU20090117A7 (es) 2011-10-05
HRP20110970T1 (hr) 2012-01-31
WO2008085506A1 (en) 2008-07-17
MY154877A (en) 2015-08-14
EA017437B1 (ru) 2012-12-28
ZA200904826B (en) 2010-09-29
CN101616592B (zh) 2013-06-05
CR10906A (es) 2009-10-23

Similar Documents

Publication Publication Date Title
TN2009000278A1 (en) 3-substituted-[1,2,3] benzotriazinone compounds for enhancing glutamatergic synaptic responses
SG163545A1 (en) 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
EA201390971A1 (ru) ИМИДАЗО[5,1-f][1,2,4]ТРИАЗИНЫ ДЛЯ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ РАССТРОЙСТВ
BRPI0817271A2 (pt) Método de tratamento da doença de parkinson e outros distúrbios relacionados
EP2340242A4 (en) COMPOUNDS FOR THE TREATMENT OF EYE DISEASES AND DRESSES
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
MY148558A (en) Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use
WO2013025997A3 (en) Brain stimulation methods for treating central sensitivity
WO2008050341A3 (en) Novel psychotropic agents having glutamate nmda activity
EP2152865A4 (en) METHOD FOR THE TREATMENT AND PREVENTION OF NEURODEEGENERATIVE DISEASES AND DISORDERS
WO2013029060A3 (en) Compositions and methods for treating neurodegenerative disease
EP2750606A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF NEUROLOGICAL AND NEURODEEGENERATIVE DISEASES, DISORDERS AND RELATED METHODS
JP2009537568A5 (es)
WO2003045315A3 (en) Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses
UA93306C2 (ru) Соединение 3-замещенного-[1,2,3]-бензотриазинона для улучшения глутаматергических синаптических реакций
EP2552473A4 (en) METHOD FOR THE TREATMENT OF MORBUS PARKINSON AND OTHER DISORDERS OF DOPAMINERGIC NEURONS OF THE BRAIN
ZA200900739B (en) N-phenyl-prenylamine derivatives for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
WO2007034326A3 (en) Imidazole compounds for the treatment of neurological disorders
WO2011015646A3 (en) Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
MX2011008060A (es) Derivados de amida biciclica para mejorar las respuestas sinapticas glutamatergicas.
HK1140209A1 (en) Receptor modulators exhibiting neuroprotective and memory enhancing activities
HK1148234A (en) Device and method for treating central nervous system pathology
TN2011000105A1 (en) Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use
HK1173654A1 (zh) 治疗化合物及相关的使用方法

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights